IMF Videos Search Content For Healthcare Professional (182) Healthcare Provider (182) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (247) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Deep and Durable Responses with Selinexor, Daratumumab, and Dexamethasome (SDd) in Patients with Multiple Myeloma (MM) Previously Exposed to Proteasome Inhibitors and Immunomodulatory Drugs December 4, 2018 ASH Safety and Efficacy of Melflufen for Relapsed Refractory Multiple Myeloma Patients December 4, 2018 ASH NKG2D-CAR Transduced Primary Natural Killer Cells Efficiently Target Multiple Myeloma Cells December 4, 2018 ASH Predictors of T Cell Expansion and Clinical Responses Following CART-BCMA for Relapsed/Refractory Multiple Myeloma December 4, 2018 ASH Pomalidomide + Low-Dose Dexamethasone + Daratumumab in Relapsed and/or Refractory Multiple Myeloma after Lenalidomide-Based Treatment Failure December 4, 2018 ASH Efficacy and Feasibility of Dose/Schedule-Adjusted Rd-R Vs. Continuous Rd in Elderly and Intermediate-Fit Newly Diagnosed Multiple Myeloma Patients December 4, 2018 ASH Safety and Efficacy of Multiantigen-Targeted T Cells for Multiple Myeloma December 3, 2018 ASH Standardization of 18F-FDG PET/CT According to Deauville Criteria for MRD Evaluation in MM Patients December 3, 2018 ASH Subcutaneous Daratumumab in Patients with Relapsed or Refractory Multiple Myeloma: Part 2 Safety and Efficacy Update of the Open-Label, Multicenter, Phase 1b Study (PAVO) December 3, 2018 ASH Las células NK primarias transducidas con NKG2D-CAR apuntan eficientemente a las células MM December 3, 2018 ASH Two-Year Update of Castor: Efficacy and Safety of Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in First Relapse Patients December 3, 2018 ASH 串联自体移植 和CD19的联合输液 和Bcma特异性CAR T细胞 对于高风险MM December 3, 2018 ASH Load More
